Pharma News

Fresenius Kabi and Formycon reach agreement with J&J, Alvotech and Teva expand partnership

Home/Pharma News | Posted 08/09/2023

In August 2023, Fresenius Kabi and Formycon announced that they have entered into a settlement agreement with Johnson & Johnson (J&J) concerning FYB202, a proposed ustekinumab biosimilar in the US. This followed the late July 2023 news that Alvotech and Teva Pharmaceuticals (Teva) have agreed to expand their existing strategic partnership agreement.

Cuba and China strengthen ties in biotechnology

Home/Pharma News | Posted 01/09/2023

The biotechnological cooperation between Cuba and China has been a longstanding relationship in the scientific and technological realms. For the benefit of both countries, Havana and Beijing have undertaken various collaborations in the field of biotechnology, driven by their bilateral relations and shared interest in the development of the healthcare and pharmaceutical industry.

New BioFactura-CuraTeQ partnership for ustekinumab biosimilar

Home/Pharma News | Posted 25/08/2023

CuraTeQ Biologics Private Limited, a subsidiary of India’s Aurobindo Pharma Limited, has entered into an exclusive license agreement to commercialize BFI-751, BioFactura’s proposed biosimilar to Stelara (ustekinumab).

Four drugmakers sue the US government over the Inflation Reduction Act

Home/Pharma News | Posted 18/08/2023

In July 2023, Johnson & Johnson became the fourth large drugmaker to sue the US government over drug price negotiations in the Inflation Reduction Act (IRA). They join, Merck, Bristol Myers Squibb and Astellas in claiming that price negotiations by Medicare violate the First and Fifth Amendments of the US Constitution.

J&J lawsuits settled over ustekinumab biosimilars

Home/Pharma News | Posted 24/07/2023

Johnson & Johnson (J&J), the maker of Stelara (ustekinumab), settled two lawsuits, one against Amgen, and the other against Alvotech and Teva Pharmaceuticals. Both lawsuits were over proposed ustekinumab biosimilars for the treatment of autoimmune conditions. These were settled in May and June 2023,respectively.

Celltrion–Rani partnership for RaniPill biosimilars

Home/Pharma News | Posted 14/07/2023

Celltrion and Rani Therapeutics (Rani) have entered a partnership under which Celltrion will supply ustekinumab and adalimumab biosimilars for RaniPill products under an exclusive license and supply agreement.

Cuba strengthens biotech industry through Eurasian partnerships

Home/Pharma News | Posted 14/07/2023

Cuba is consolidating its position in the field of biotechnology thanks to cooperation with several Eurasian nations, in particular Russia and Belarus.

Biosimilars manufacturing facilities approved by EU and US

Home/Pharma News | Posted 06/06/2023

Two biological drugs manufacturing facilities for biosimilar epoetin alfa and biosimilar bevacizumab were approved in the US and Europe in May and April 2023, respectively.

Cuba and China strengthen scientific cooperation for the development of medical treatments

Home/Pharma News | Posted 30/05/2023

In recent years, Cuba and China have established agreements to develop innovative medical treatments, notably Center for Genetic Engineering and Biotechnology (Centro de Ingeniería Genética y Biotecnología, CIGB) and Center for Molecular Immunology (Centro de Inmunología Molecular, CIM), and have shared their experiences in the field of medical research.

HK inno.N–mAbxience partnership in Korea and Coherus advances in the US

Home/Pharma News | Posted 17/02/2023

In early 2023, it was announced that South Korea’s HK inno.N signed an exclusive license agreement with Spain's mAbxience to bring a denosumab biosimilar to market in South Korea. In addition, in the US, Coherus BioSciences is to acquire exclusive commercial rights to Formycon’s under-development Eylea (aflibercept) biosimilar.